Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07258290 · ClinicalTrials.gov registry record · NA
Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold (RMS) System in Subjects With Coronary Artery Lesions
A NA study, sponsored by Teleflex.
- Recruiting
- Registry status
- NA
- Development phase
- 1,859
- Enrollment target
NCT07258290 is a NA study that is actively recruiting participants, run by Teleflex. The registered enrollment target is 1,859 participants.
The verdict
NCT07258290, a NA study, is actively recruiting participants, sponsored by Teleflex.
- RECRUITING
- Registry status
- NA
- Development phase
- 1,859 participants
- Enrollment target
Study Summary
The objective of this study is to assess the safety and efficacy of the Freesolve resorbable magnesium scaffold (RMS) in the treatment of subjects with up to two de novo lesions in native coronary arteries compared to the Xience coronary drug-eluting stent (DES) system
Interventions
- DEVICE Freesolve RMS
- DEVICE Xience DES
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,859 participants |
| Start Date | 2026-06-11 |
| Est. Completion | 2033-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07258290
The ClinicalTrials.gov registry entry for NCT07258290 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 1,859 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teleflex, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Freesolve RMS is the first listed.
NCT07258290 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07258290 about?
NCT07258290 is a clinical study titled "Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold (RMS) System in Subjects With Coronary Artery Lesions". The objective of this study is to assess the safety and efficacy of the Freesolve resorbable magnesium scaffold (RMS) in the treatment of subjects with up to two de novo lesions in native coronary arteries compared to the Xience coronary drug-eluting stent (DES) system
What is the current status of trial NCT07258290?
This trial is currently recruiting. It is a NA study. The enrollment target is 1,859 participants. The study started on 2026-06-11. Estimated completion is 2033-06.
What interventions are being tested in trial NCT07258290?
The interventions under investigation include: Freesolve RMS (DEVICE), Xience DES (DEVICE).
Who is sponsoring clinical trial NCT07258290?
This trial is sponsored by Teleflex, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.